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ABSTRACT 
Head and neck cancer is the sixth most common cancer worldwide. Despite 
advances in diagnosis and treatment, the survival rates for patients with head and neck 
cancer have remained relatively unchanged for the past 30 years. Head and Neck 
Squamous Cell Carcinoma is a highly aggressive malignancy with a 5-year survival rate of 
only 500/0. Of the patients diagnosed every year, 5% of head and neck squamous cell 
carcinoma (HNSCC) patients develop additional primary tumors, an effect that is thought 
to be associated with the high degree of immune suppression induced by the tumor. During 
the premalignant stage of HNSCC, there is an increase in the number of helper T subset 
Th17 cells, which then decreases in fully established HNSCC. The focus of our laboratory 
is on delineating the role ofTh17 cells in HNSCC tumor development. Thus, the goal of 
this study is to elucidate the role of the tumor microenvironment in the decrease in Th17 
cells observed in established HNSCC. We hypothesize that the decrease in Th17 cells is 
due to changes that occur in the tumor microenvironment during the transition from 
premalignant tissue to established HNSCC. To examine this, we characterized the cytokine 
levels in normal, premalignant and HNSCC tongue tissues. We also investigated the role of 
the microenvironment in the decrease in Th17 cell numbers observed in fully developed 
HNSCC compared to the premalignant stages. Our data showed an inflammatory response 
at the microenvironment which included both an increase in inflammatory cytokines as 
well as an increase in ThI7 cells. This response was later attenuated during the HNSCC 
stage. When incubated with supernatant from premalignant tissue, ThI7 cells maintained a 
tV 
higher level ofIL-17 when compared to incubating with supernatant from control or 
HNSCC tissue. The opposite was found when splenocytes were incubated with these same 
supernatants. The levels of IL-l 7 dropped when incubated with supernatant from 
premalignant tissue when compared to control or HNSCC. 
v 
Chapter 1 
Tumor environment and HNSCC 
CHAPTER 1: TUMOR ENVIROMENT AND HEAD AND NECK SQUAMOUS CELL 
CARCINOMA 
1.1 Clinical development of HNsee 
Despite advances in diagnosis and treatment, the survival rates for patients with 
head and neck cancer have remained relatively unchanged for the past 30 years [1]. 
HNSCC is a highly aggressive malignancy with a 5-year survival rate of only 50%. Of 
the patients diagnosed with HNSCC, 5% of HNSCC patients develop additional primary 
tumors [2-3]. This is thought to be associated with the high degree of immune 
suppression induced by the tumor [4-5]. Treatment of this malignancy is further 
complicated by the significant morbidity associated with surgery. Identification of the 
differences in the tumor microenvironment during the different stages of HNSCC 
pathogenesis would provide a foundation for the development of immunotherapeutic 
interventions for patients diagnosed with premalignant lesions or HNSCC. 
HNSCC develops from keratinizing epithelial cells, most commonly at the lateral and 
ventral surfaces of the tongue, the anterior floor of the mouth, and the lip [6-7]. Initially 
asymptomatic, the first indication of disease is the appearance of thick adherent plaques, 
known as leukoplakias or erythroplakias [6]. If left untreated, these lesions can develop into 
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exophytic or ulcerative malignant tumors [6]. Though premalignant lesions may be 
removed, patients with high risk plaques have a significant risk of developing secondary 
premalignant lesions and HNSCC [6-8]. Local recurrence and regional lymph node spread 
are the predominant causes of the high mortality observed in patients with HNSCC [5-8]. 
Because it is believed that immune suppression in these patients contributes to morbidity 
and recurrence, attenuating this immune suppression represents a potential therapeutic 
option. 
1.2 Immunosuppression in established UNSee 
Head and neck squamous cell carcinomas (HNSCCs) are associated with 
abnormal cell-mediated immunity at the primary tumor site [9]. The level of 
immunosuppression in patients with HNSCC varies widely. Immunosuppression in 
HNSCC has been postulated to occur in a hierarchical manner, in which the primary 
tumor region is the most affected site, followed by the draining lymph nodes [10]. This 
hierarchical phenomenon suggests that immunosuppression in HNSCC patients is 
mediated by a regional network of factors. It is likely that immune suppression at the site 
of the tumor and affected lymph nodes plays a role in limiting the efficacy of current 
immunotherapy protocols. It also likely that the immune system exerts a selective 
pressure that gives rise to the tumor variants that are then able to manipulate the immune 
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system [11-16]. A greater understanding of the mechanisms of local inhibition of immune 
function will aid in improving adoptive immunotherapy for the treatment of cancers [10]. 
While the onset of head and neck cancer is linked to environmental carcinogens 
(tobacco, alcohol), tumor progression itself appears to be linked to failure of the immune 
system [17]. In addition to escaping immune system surveillance, some head and neck 
cancers are also able to corrupt the antitumor response via several mechanisms [18]. 
These include targeting the antigen presenting machinery (APM) via the down regulation 
or loss of expression of human leukocyte antigen (HLA) class I molecules and/or other 
components of the APM [11,19]. Although effective antitumor immune responses likely 
involve multiple components of the immune system, T -cells are considered the most 
critical cells involved in antitumor immunity. 
Recent evidence suggests that antitumor responses in HNSCC patients are 
compromised by functional defects or apoptosis of T -cells, both circulating and tumor-
infiltrating [13-16]. Hoffmann et al. showed that the FaslFasL pathway is involved in the 
spontaneous apoptosis of circulating F as + T lymphocytes [16]. In fact, tumor-infiltrating 
lymphocytes (TILs) look like activated T cells but are functionally compromised. They 
can have absent or low expression of the CD3 zeta chain (a key signaling molecule) and 
they exhibit decreased proliferation in response to mitogens or IL-2 [11]. Some lack the 
ability to kill tumor cell targets [15-16] or demonstrate an imbalanced cytokine profile, 
with the striking absence oflL-2 and/or IFN-y production [20]. There is also evidence of 
pronounced apoptotic features in a considerable proportion of TILs [11,21]. In addition, 
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HNSCC cells produce high quantities of TGF -J31, which reduces the expression of 
natural killer (NK) cell receptor NKG2D and CD16, which inhibits the biological 
function ofNK cells and increases the level of Tregs in peripheral blood mononuclear 
cells in head and neck cancer patients [22]. 
1.3 Immunoediting 
Immunoediting is a process that is responsible for both eliminating tumors and 
shaping the immunogenic phenotypes of tumors that eventually form in 
immunocompetent hosts. Elimination is the first stage of this process. Immune cells 
patrol the body, recognizing transformed cells and eliminating them in a mechanism 
involving Thl cells and macrophages. Severe-combined immune-deficiency (SCID) mice 
or mice that lack recombination activating gene (RAG-1-), leads to the absence of T cells, 
B cells, and Natural Killer cells, exhibit increased susceptibility to chemically-induced 
tumors [23-25]. Patients with immunodeficiencies are also at an increased risk for 
carcinogenesis, whether the cancers are of a viral or non-viral etiology [26-28]. In a 
response known as a type 1 response, T helper type 1 (Thl) lymphocytes secrete 
interleukin (IL)-2, interferon-y, and lymphotoxin-a and stimulate type 1 immunity, which 
is characterized by intense phagocytic activity. This type 1 response was identified as the 
main effector of immunosurveillance after finding that rnice with specific deletion of 
CD4+ and/or CD8+ cells, antibody mediated neutralization or knockout ofIFN-y, or 
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knockout ofIL-12, perforin or TNF-related apoptosis-inducing ligand (TRAIL) all 
experienced an increased incidence and/or growth of several different types of cancer 
[29-33]. Conversely, a type 2 response involves Th2 cells that secrete IL-4, IL-5, IL-9, 
IL-10, and IL-13, and is characterized by high antibody titers. Type 1 and type 2 
immunity are not strictly synonymous with cell-mediated and humoral immunity, 
because Th1 cells also stimulate moderate levels of antibody production, whereas Th2 
cells actively suppress phagocytosis [34]. 
Once a solid tumor reaches a certain size, it begins to grow invasively and 
requires an enhanced blood supply, which is facilitated by the production of stromagenic 
and angiogenic proteins [35]. Invasive growth causes minor disruptions within the 
surrounding tissue that induce inflammatory signals leading to the recruitment of cells of 
the innate immune system; natural killer T cells (NKT), natural killer cells (NK), y8 T 
cells, macrophages and dendritic cells [36-38]. Molecules on the surfaces of transformed 
cells are recognized by infiltrating lymphocytes (NK, NKT, or y8 T cells), which are 
stimulated to produce IFN-y [39-41]. The IFN-y that is produced by these cells can cause 
small amounts of tumor death through anti-proliferative [42] and apoptotic [43] 
mechanisms. It also induces the production of chemokines from tumor cells and the 
normal surrounding tissue, some of which exert angiostatic effects leading to additional 
tumor death. Chemokines produced during the inflammation process also recruit NK cells 
and macrophages to the site. These tumor infiltrating NK cells and macrophages then 
transactivate one another by reciprocal IFN-y and IL-12 production to eliminate 
additional tumor cells via tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL), perf orin, reactive nitrogen species and nitrogen intermediates [30]. Finally, 
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tumor-specific CD4+ and CD8+ T cells hone to the tumor site, where the cytolytic T cells 
destroy the remaining antigen-bearing tumor cells whose evasion ability has been 
enhanced by exposure to locally produced IFN-y [23]. 
During Equilibrium, the host immune system and tumor cell variants that have 
survived the elimination process enter into a dynamic equilibrium. During this stage, 
lymphocytes and IFN -y exert potent pressure on the tumor cells that is enough to contain, 
but not fully extinguish, a tumor bed containing many genetically unstable and rapidly 
mutating tumor cells. During this time period, although many of the original variants of 
the tumor are destroyed, new variants arise that contain mutations that provide them with 
increased resistance to immune attack. This process is likely the longest of the three, 
occurring possibly even over a period of years [44]. 
The last phase, Escape, involves the surviving tumor variants that have escaped 
immunologic detection and/or elimination through genetic or epigenetic changes and 
begin to expand in an uncontrolled manner. This results in a clinically observable 
malignant disease that, if left unchecked, results in the death of the host [44]. Established 
tumors have been shown to evade immune recognition through the downregulation of 
immunogenic markers and/or MHC class I molecules [45-46]. In escape, tumors develop 
the ability to down-regulate the type I effector response and upregulate the type II 
effector response, which, while beneficial under certain conditions, is most often 
associated with a poor prognosis in cancer patients. Reduced IL-12 levels in cancer 
patients has been shown to reduce the number of Cytotoxic T Lymphocytes (CTLs) and 
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reduced IFN -y has been shown to reduce the induction of MHC class I and II and directly 
induce T cell anergy [47-49]. In contrast to type I cytokines, the type II cytokines IL-4, 
IL-I0 and TGF -13 have all been shown to be upregulated in patients with many types of 
advanced cancers [50-55]. IL-4 directly inhibits Thl cell differentiation, downregulates 
IFN-y production, and upregulates the type II response [56-60]. Like IL-4, IL-IO 
downregulates IFN-y production [59]. It has also been shown to reduce IL-12 production, 
downregulate MHC surface expression, and induce tumor-associated T cell tolerance 
[61-64]. TGF-J3 affects the immune system in multiple ways. It has been shown to reduce 
the differentiation, proliferation and functional capacity of T cells, including 
downregulation of the Thl response by inhibition oflL-2 and IFN-y production by Thl 
cells and inhibition ofFAS ligand and perforin expression on CTLs [65-71]. TGF-J3 also 
inhibits co-stimulation, antigen presentation, maturation and IL-12 production by antigen 
presenting cells, further downregulating the type I response [72-73]. Finally, TGF-J3 has 
been shown to increase tumor production of prostaglandin E2 (PGE2) and vascular 
endothelial growth factor (VEGF), both of which promote tumor growth through multiple 
pathways [74-77]. These changes in the cytokine milieu contribute significantly to the 
blockade of a functional antitumor immune response in the microenvironment of many 
established tumors. 
1.4 Th17 cells 
Since their discovery only five years ago, Th17 cells have risen to prominence in 
studies of virology, autoimmune disease, inflammation, and immune responses to various 
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parasites and fungi. While their role in the pathogenesis of many of these conditions is 
well defined, their function in the context of tumor immunology remains controversial. 
Th 1 7 cells are defined as CD4 + helper T cells that secrete IL-l 7, and whose 
developmental program is controlled by multiple cytokines and the transcription factor 
RAR-related orphan receptor gamma T (RORyT) (78). 
It has been shown that human tumor-associated Th17 cells express minimal levels 
ofHLA-DR, CD25, and granzyme B, suggesting that they are not a "conventional" 
effector cell population [79]. Moreover, these cells also do not express programmed cell 
death 1 (PD-l) or forkhead box P3 (FoxP3), making it unlikely that they induce immune 
suppression through either pathway [79]. Tumor-associated Th17 cytokine products 
mimic those found in some instances of viral infection [80-81]. Tumor-associated Th 17 
cells highly express CXCR4 and CCR6, the c-type lectin receptor CD161, and the CD49 
integrin isoforms c, d, and e. Although ccru, CCR5, and CCR7 are not present on these 
cells [82], CCR6 and CD161 have been observed both on Th17 cells from healthy donors 
and on lymphocytes and dendritic cells in inflammatory environments [83-85]. Sharma et 
al. identified a similar Th17 phenotype in a mouse model of cancer [86]. Therefore, it 
appears that in both human and mouse malignancies, Th17 cells share the same effector 
cytokine profile. 
In ovarian cancer, the prevalence of Th 17 cells in tumor draining lymph nodes 
(TDLN) and blood is comparable to that of healthy donors. Although they make up only 
a small population of cells within the tumor microenvironment, they are proportionally 
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higher there in comparison to other immune cell subsets. Tumor-associated Th17 levels 
correlate positively with microenvironmental Thl cells, cytotoxic CD8+ T cells, and NK 
cells, and are inversely correlated with Tregs [82,87]. Su et al. also reported significantly 
higher numbers ofTh17 cells expanded or induced from tumor infiltrating lymphocyte 
populations in cancer patients than from lymphocyte populations from non-tumor tissues 
[88]. 
The IL-17 cytokine family can induce the production of other proinflammatory 
cytokines, chemokines, and prostaglandins. There are six family members (A-F) that are 
expressed by a variety of innate and adaptive immune cell types. Zhang et al. examined 
IL-17+ cells in patients with hepatocellular carcinoma (RCC) and suggested a potential 
pro-tumorigenic role for IL-17. Increased IL-17-producing cell density within RCC 
tumors correlated with both microvessel density and poor prognosis [89]. Notably, HCC 
is strongly associated with chronic viral he~at~tis, and chronic viral infection may 
profoundly reshape the generation and function of Th 17 cells in cancer patients. In 
non-small cell lung carcinoma (NSCLC) patients, higher levels of IL-l 7 within the tumor 
correlated with higher blood vessel density and shorter survival time [90]. 
In ovarian cancer patients, Th 1 7 cells were the sole source of IL-l 7 in the ascites, 
and the level of IL-17 in this fluid correlated positively with patient survival. Even after 
debulking, tumor-associated IL-l 7 was a negative predictor of death hazard. The average 
survival rate of patients with levels of IL-l 7 greater than 220 pg/ml in ascites was 78 
months, while that of patients with less than 220 pg/ml was 27 months. In the tumor 
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microenvironment, IL-17 synergized with IFN -y to induce CXCL9 and CXCL 1 0 
production. These Thl-type chemokines recruit effector populations to the tumor itself, 
and ascites levels of CXCL9 and CXCL 1 0 correlated directly with the prevalence of 
tumor-infiltrating NK and CD8+ T cells [82]. In agreement with this, Sfanos et al. 
showed an inverse correlation between the levels of Th 1 7 cells in prostate glands and 
tumor progression [91]. However, in another study examining patients with honnone 
resistant prostate cancer, Derhovanessian et al. demonstrated an inverse correlation 
between pre-treatment circulating levels of Th 1 7 cells and time to disease progression 
[92]. A recent report by Zhang, et ale found no correlation between Th17 cells and 
clinicopathological characteristics or survival in patients with nasopharyngeal carcinoma 
[93]. Ye and colleagues investigated Th17 cells from 30 patients with lung 
adenocarcinoma or squamous cell carcinoma and found that a higher accumulation of 
Th17 cells in malignant pleural effusion (MPE) predicted improved patient survival [94]. 
In some types of epithelial cancer, Th 1 7 cefis ~onstitute only a small fraction of the 
effector T cell population in the tumor microenvironment [78,82,95-96]. This has not 
been fully investigated in HNSCC. 
Because few studies have focused on primary Th 1 7 cells in the tumor 
microenvironment, it is difficult to predict the exact role( s) they may play in cancer 
progression. In patients with epithelial cancer, Th 1 7 levels are an indicator of improved 
patient survival and reduced tumor progression. In mice with established tumors, studies 
have documented the potent antitumor efficacy of both Tc17 and Th17 populations. It is 
possible that Th17 function may vary dependent on the cause, type and location of the 
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cancer [97]. For example, accumulated data suggest that Th17 cells and/or IL-17, along 
with other factors, induce inflammation and promote the initiation and early growth of 
tumors in three different murine models of cancer: immune-deficient mice, mice with 
chemical carcinogen-induced tumors, and mice with pathogen-induced tumors [79]. This 
occurs despite high levels of IL-6, TGF-B, and IL-l, factors that promote mouse Th17 
cell development [98-100], suggesting that Th 17 cell development may be suppressed in 
the tumor microenvironment. In support of this, Th 1 7 cells are tightly regulated by the 
local cytokine environment [78] and Treg cells inhibit Th17 cell expansion [82,95]. 
Th17 differentiation is potently driven by TGF-B and IL-6 [101-102] and is 
reinforced by IL-23 [103-104]. The Th 17 -specific master transcription factors retinoic 
acid-related orphan receptor (ROR)yt and RORu, two orphan nuclear receptors, have 
been recently shown to regulate Th 1 7 differentiation [105-106]. It has been thought that 
~ ,.. 
effector differentiation is a "terminal" process 'for naive Th cells; however, recent results 
suggest the plasticity of Th subsets. For example, it has been reported that Foxp3+ 
regulatory T cells can be reprogrammed to become Thl7-like cells by IL-6 and other 
proinflammatory cytokines [107] 
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Chapter 2 
Rationale, Hypothesis, and Specific Aims 
;. 
CHAPTER 2: RATIONALE, HYPOTHESIS, AND SPECIFIC AIMS 
2.1. Rationale 
The National Cancer Institute predicted that more than 52,000 men and women in 
the United States would be diagnosed with head and neck cancers in 2011 [1]. Despite 
advances in diagnosis and treatment, the survival rates for patients with head and neck 
cancer have remained relatively unchanged for the past 30 years [1]. HNSCC is a highly 
aggressive malignancy with a 5-year survival rate of only 50% and in addition, every 
year, 5% ofHNSCC patients develop additional primary tumors [2-3]. HNSCC is 
associated.with the high degree of immune iuppression induced by the tumor [4-5], 
which could be the cause for the level of recurrence. While systemic immune suppression 
is a hallmark of HNSCC, immune suppression during the premalignant stage is believed 
to be restricted to the local environment. By identifying the changes that occur in the 
microenvironment during the transition from normal tissue to premalignant tissue to 
HNSCC we may better understand the role of immunosuppression and better yet, 
understand how to prevent it. Because few studies have focused on the role ofTh17 cells 
in the tumor microenvironment, it is difficult to deduce the exact role( s) they may play in 
cancer progressIon. 
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In some cancer types, increased Th 1 7 cells and elevated IL-l 7 is an indicator of 
poor prognosis, while in other types of cancer it is indicative of a positive outcome [79]. 
In mice with established tumors, studies have documented the potent antitumor efficacy 
of both Tc 17 and Th17 populations. Thus, Th17 function may vary dependent on the 
cause, type and location of the cancer [79]. 
2.1.1 Hypothesis 
To understand the role of the tumor microenvironment in immune suppression, it 
is crucial to understand the phenotypic differences and cytokine variations that occur 
during the different stages ofHNSCC development. Our laboratory has previously shown 
that IL-17 A levels are decreased in cervical lymph nodes of mice with fully established 
HNSCC compared to premalignant or control. We hypothesized that there will be a 
decrease in IL-17A in the microenvironnien~ resulting from changes that occur 
during the transition from premalignant tissue to established HNSCC. 
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2.1.2. Specific Aims 
This hypothesis was tested through the following specific aims: 
Aim 1. Characterization of the cytokine levels in normal, premalignant and HNSCC 
tongue tissues from both human samples and a mouse model. 4-nitroquinoline-I-oxide 
(4NQO) was used to generate premalignant lesions or HNSCC in a mouse model. 
Tongue tissue was then enzymatically digested and stimulated with PMA and Ionomycin. 
U sing a cytometric bead array, we analyzed the cytokine levels secreted from tissue from 
nonnal, premalignant and HNSCC-bearing tongue tissue. Human premalignant and 
HNSCC tissue was collected through one of the IRB approved protocols and normal 
adjacent tissue was collected from a tumor bank. The tissue was lysed and the cytokine 
levels were analyzed using the same cytometric bead array. 
Aim 2. Investigation of the role of the microenvironment in the decrease in Th17 cell 
numbers observed in HNSCC tissue compared to premalignant tissue. Polarized mouse 
Thl7 cells were exposed to supernatant from normal, premalignant or HNSCC tongue 
tissue to determine the effects of the tumor microenvironment on the Th 1 7 cell 
population. Supernatants from this co-incubation were collected and cytokine levels were 
analyzed by cytometric bead array. The same supernatants were then co-incubated with 
splenocytes and the cytokine levels from this were also analyzed by cytometric bead 
array. 
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2.2. Importance 
This aim of this study is to further define the role of the microenvironment in the 
progression of HNSCC. HNSCC is the sixth most common cancer worldwide, with few 
treatment options and a high mortality rate. A better understanding of the mechanisms by 
which this disease progresses will aid in the development of more effective treatments. 
:. 
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Chapter 3 
Characterization of Cytokines in the Tumor 
Microenvironment 
CHAPTER 3: CHARACTERIZATION OF CYTOKINES IN THE TUMOR 
MICROENVIRONMENT 
Aim 1: To characterize the cytokine levels in normal, premalignant and HNSCC 
tongue tissues from both human samples and a mouse model. 
3.1 Introduction 
The National Cancer Institute predicted that more than 52,000 men and women in 
the United States would be diagnosed with head and neck cancers in 2011 [1]. Despite 
advances in diagnosis and treatment, the survival rates for patients with head and neck 
cancer have remained relatively unchanged for the past 30 years [1]. HNSCC is a highly 
aggressive malignancy with a 5-year survival rate of only 50%. In addition, every year, 
5% of HNSCC patients develop additional primary tumors [2-3]., an event thought to be 
associated with the high degree of tumor-induced immune suppression [4-5]. While 
systemic immune suppression is a hallmark of HNSCC, immune suppression during the 
premalignant stage of HNSCC is believed to be restricted to the local environment. By 
identifying the changes that occur in the microenvironment during the transition from 
normal tissue to premalignant tissue to HNSCC, we may better understand the role of 
immunosuppression. More importantly, this knowledge may allow us to prevent it. A 
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greater understanding of the mechanisms of local inhibition of immune function will aid 
in improving adoptive immunotherapy for the treatment of cancers [10]. Here, we 
characterize the microenvironments found in nonnal, premalignant and HNSCC tissue to 
better understand the mechanisms by which the local immune system is suppressed and 
which cell types are affected. 
3.2 Materials and Methods 
Oral HNSCC carcinogenesis 
Carcinogen~induced oral premalignant lesions and HNSCC was established in 
mice by the administration of 4NQO at 5 mg/ml in propylene glycol stock in the drinking 
water (diluted to 50 Jlg/ml) of2-month old (at start) female C57BL/6 mice. 4NQO was 
left in their water for 8 weeks, to induce the development of premalignant oral lesions 
detectable on the tongue, or for 16 weeks to establish HNSCC. To monitor the 
development of premalignant oral lesions and HNSCC, the oral cavities of the mice were 
examined by endoscopy using a Stryker 1.9 mm x 30 0 endoscope and a Stryker 1088 HD 
camera. The mice were sedated with inhaled isoflurane (Piramal Healthcare) during this 
procedure. 
Oral carcinogenesis classification 
To monitor the development of premalignant oral lesions and HNSCC, the oral 
cavities of the mice were examined by endoscopy using a Stryker 1.9 mm x 30° 
endoscope and a Stryker 1088 HD camera. The mice were sedated with inhaled 
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isoflurane (Piramal Healthcare) during this procedure. Classification was done based on 
the size and type of lesion. For those only classified as premalignant and HNSCC, the 
lesions are considered premalignant when leukoplakias are present that are flush with the 
tongue (Fig. 3.1.B), the lesions are considered HNSCC once they become exophytic (Fig. 
3.1.D) For those considered early and late premalignant or HNSCC, early premalignant is 
the first sign of a leukoplakia (Fig. 3.t.B), late premalignant is when there are extremely 
large or multiple leukoplakias (Fig. 3.1.C). Early HNSCC is the first appearance of an 
exophytic lesion (Fig. 3.1.0), late HNSCC is presence of an extremely large or multiple 
exophytic lesions (Fig.3.1E). 
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A. B. c. 
D. E. 
Figure 3.1. Levels of IL-6, IL-2, and TGF -p change in the microenvironment during 
the progression of HNSCC. Pictorial representation of the stages of carcinogenesis 
resulting from 4NQO treatment. Normal tongue (A), Stage is considered premalignant 
when leukoplakias are present that are flush with the tongue (B), Stage is considered late 
premalignant when there are extremely large or multiple leukoplakias (C), Stage is 
considered HNSCC once the lesions become exophytic (D), Stage is considered late 
HNSCC when the exophytic lesions are extremely large or there are multiple exophytic 
lesions (E). 
Tongue tissue processing 
Control, premalignant, and HNSCC tongues were harvested from C57BL/6 mice 
and minced using a scalpel. The tissue was then enzymatically digested at 37°C with 
0.23U of Liberase (Roche) for 4 hrs. The tissue was washed with PBS and allowed to 
recover overnight. 
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Human samples 
Recruitment of patients into this study was approved by the Institutional Review 
Board of record. Tissue samples were collected from patients bearing premalignant 
lesions or HNSCC tumors. Normal, non-carcinogenic oral tissue was procured from the 
adjacent areas bordering the cancerous tissue, and these tissues were deemed 
pathologically normal with no microscopic evidence of invasive carcinogenic disease. 
These samples were cryopreserved at -80°C until they were used for cytokine analysis. 
Cytokine bead array 
All reagents used in this assay were from BD unless otherwise specified. The day 
following the enzymatic digestion, the tongue tissue was stimulated for 4 hours at 37°C 
with 50 ng/ml PMA and 1 Jlg/ml ionomycin without the addition of Brefeldin A. Both 
mouse and human tissues were lysed through sonication and protein concentrations were 
detennined by BCA protein assay (Pierce). Final cytokine levels in tissue were expressed 
as pg/lOO Jlg of protein. The levels ofIFN-,)" IL-2, IL-17 (IL-17A), IL-4 and IL-I0 in 
tissue lysate or supernatant were determined using a cytometric bead array Th I /Th2/Th 17 
cytokine kit, while the levels of active TGF-p in tissue lysate or supernatant were 
determined using cytometric bead array flex sets according to the manufacturer's 
instructions. Relative amounts of each cytokine were analyzed using FCAP Array 
software. 
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Statistical analysis 
Data are reported as the measure ± standard deviation of the value. To compare 
one variable condition between groups, the two-tailed Student's I-test was used. 
Significance was reported in the 95% confidence interval. 
3.3 Results 
Changes in the tumor microenvironment during the progression of HNSCC. 
Head and neck squamous cell carcinomas (HNSCCs) are associated with 
abnormal cell-mediated immunity at the primary tumor site [9]. The level of 
immunosuppression in patients with HNSCC varies widely. Immunosuppression in 
HNSCC has been postulated to occur in a hierarchical manner, in which the primary 
tumor region is the most affected site, followed by the draining lymph nodes [10]. This 
hierarchical phenomenon suggests that immunosuppression in HNSCC patients is 
mediated by a regional network of factors. It is likely that suppression at the site of the 
tumor and the affected lymph nodes plays a role in limiting the efficacy of current 
immunotherapy protocols [11-16]. Although effective antitumor immune responses likely 
involve multiple components of the immune system, T -cells are considered the critical 
cells involved in antitumor immunity. 
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Recent studies have shown that some of these cells lack the ability to kill tumor cell 
targets [15-16] or demonstrate an imbalanced cytokine profile, with a striking absence of 
IL-2 and/or IFN-y production [20]. HNSCC cells also produce high quantities ofTGF-Bl, 
which reduces the expression of the natural killer (NK) cell receptor NKG2D and CD 16, 
inhibits the biological function of NK cells, and increases the level of Tregs in peripheral 
blood mononuclear cells in head and neck cancer patients [22]. 
To detennine the composition of cytokines in the tumor microenvironment, 
tongue tissue samples taken from 4NQO-treated mice at the premalignant stage or with 
fully established HNSCC were processed and analyzed. Cytokine levels were determined 
by flow cytometric analysis using a cytometric bead array. The premalignant mice 
showed a marked increase in both IL-2 (Fig 3.2.a) and IL-6 (Fig 3.2.b) compared to 
control mice and mice with established HNSCC. They also showed a decrease in TGF-~ 
during the early premalignant stage, which increased during the late premalignant stage 
(Fig 3.1.c). This data indicated that the early premalignant stage is marked by an 
inflammatory response at lesion site that decreases once the premalignant lesions develop 
into fully established HNSCC tumors. 
















Figure 3.2. Levels of IL-6, IL-2, and TGF -p change in the microenvironment during 
the progression of HNSCC. Graphical representation of the results of cytometric bead 
array analysis of control, 4NQO-treated premalignant, and 4NQO-treated HNSCC 
tissues. For graph A and B; control (n= 7), premalignant (n=6), HNSCC (n=16). For 
graph C; control (n= 7), early premalignant (n=5), late premalignant (n=3), early HNSCC 
(n=4), late HNSCC (n=13). Data are presented as the mean ± standard deviation. *,p < 
0.05; **,p < 0.01; *** p <0.001 (Two-tailed Student's t-test). 
IL-17 A levels are increased in premalignant stage compared to control and HNSCC in 
human samples and the 4NQO mouse model. 
Patient samples of normal/adjacent, premalignant, and HNSCC tissue were 
collected and analyzed by cytometric bead array after being lysed. Control, premalignant, 
and HNSCC tongue tissues were collected from 4NQO treated mice. The tissue was 
stimulated with PMA and ionomycin after enzymatic digestion and the supernatants were 
was also analyzed by cytometric bead array. In both the human samples and in the mouse 
tissue the premalignant stage showed a significant increase in IL-17 when compared to 
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control and HNSCC. The mouse model was further broken down into early and late 
stages of premalignant and HNSCC to further elucidate the time at which this increase 
and decrease occurs. It was found that the late premalignant stage is when the increase in 













Figure 3.3. Both human and mouse samples show an increase in IL-17 A in 
premalignant tissue compared to control/normal and HNSCC tissues. Graphical 
representation of the results of cytometric bead array analysis of control, 4NQO-treated 
premalignant, and 4NQO-treated HNSCC tissues from mice (left panel) or 
normal/adjacent, premalignant, and HNSCC human tissue (right panel). For human data; 
normal/adjacent (n=lO), premalignant (n=6), HNSCC (n=25). For mouse data; control 
(n=5), early premalignant (n=6), late premalignant (n=5)m early HNSCC (n=7), late 
HNSCC (n=12). Data are presented as the mean ± standard deviation. *,p < 0.05; **,p < 
0.01; *** p < 0.001 (Two-tailed Student's t-test). 
3.4 Discussion 
Depending on the microenvironment, as well as many other factors, the immune 
system can either mount an immune response against dysplastic cells or contribute to 
tumor development and progression. Because each component of the immune system can 
be both beneficial and detrimental, it is important to evaluate the changes that occur 
between the normal, premalignant, and established stages of HNSCC development. This 
study investigated the changes that occur in various cytokine levels in the 
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microenvironment during the carcinogenesis of HNSCC using both samples from human 
patients and a chemically-induced mouse model ofHNSCC. Previously, our lab has 
shown that mice that have developed premalignant lesions exhibit an increased number of 
Th 17 cells in the spleen and cervical lymph nodes compared to control mice and mice 
with HNSCC[108]. The data presented above show that the amount ofIL-17 is increased 
in the microenvironment of both human and mouse premalignant tissues. To further 
elucidate the changes that occur during the pathogenesis of HNSCC, the mouse model 
was broken down into the early and late premalignant stages and HNSCC, and the IL-17 
levels were calculated for each of these stages. The results showed that IL-17 levels 
increase as the premalignant stage progresses and then decrease in established HNSCC, 
with the lowest levels of expression occurring during late-stage HNSCC. This data is 
supported by the marked increase in IL-6 observed in the microenvironment during the 
premalignant stage, as IL-6 and TGF .. ~ are necessary for the differentiation ofTh17 cells. 
There was also an increase in the levels of IL-2, which is necessary for the maintenance 
and stability of effector T cells. This data indicates that during the premalignant stage of 
HNSCC, an immune response is mounted. Once the lesion is allowed to progress to 
established HNSCC, this immune response is decreased. In addition, the number of 
Tregs in the spleen and cervical lymph nodes has been shown to be increased in mice 
with fully established HNSCC when compared to control and mice at the premalignant 
stage ofHNSCC[108]. As Tregs and Th17 cells have been shown to have an inversely 
proportional relationship, the decrease in IL-l 7 observed in this study may be due to an 
increase in the Treg population. 
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Chapter 4 
Effect of the Microenvironment on the CD4+ 
Population 
CHAPTER 4: MICROENVIRONMENT EFFECT ON THE CD4+POPULATION 
Aim 2: Investigation of the role of the microenvironment in the decrease IL-17 in 
HNSCC tissue compared to premalignant tissue. 
4.1 Introduction 
Despite advances in diagnosis and treatment, the survival rates for patients with 
head and neck cancer have remained relatively unchanged for the past 30 years [1]. 
HNSCC is a highly aggressive malignancy with a 5-year survival rate of only 50%. Of 
the patients diagnosed with HNSCC, 5% will develop additional primary tumors [2-3]. 
This effect is believed to be associated with the high degree of immune suppression 
induced by the tumor [4-5]. Treatment of this malignancy is further complicated by the 
significant morbidity associated with surgery. Identification of differences in the tumor 
microenvironment during the different stages ofHNSCC and the role ofTh17 cells in 
disease progression will provide a foundation for the development of immunotherapeutic 
interventions for patients with premalignant lesions or HNSCC. 
Premalignant oral lesions likely induce local immune suppression, rather than 
systemic immune suppression, as is observed in HNSCC [4,109]. The current study was 
designed to investigate the mechanisms that mediate this difference in immune 
suppression. Because few studies have focused on the function of Th 17 cells in the tumor 
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microenvironment, it is difficult to deduce the exact role( s) they play in cancer 
progression. While their role in the pathogenesis of a number of conditions is well 
defined, their function in the context of tumor immunology remains controversial. To 
further elucidate the role of the microenvironment on the increase/decrease of certain cell 
phenotypes, we manipulated the culture conditions of established Th17 cells. By 
exposing splenocytes, which are roughly 10% CD4+ cells, and polarized Th17 cells to the 
microenvironment of control, premalignant, and HNSCC tissues, we were able to 
evaluate the effects of these microenvironments on the CD4+ population. Based on data 
obtained previously from cervical lymph nodes, we expected to see a decrease in Th 17 
cell numbers and an increase in Tregs when polarized Th 17 cells were exposed to the 
HNSCC microenvironment, while Th17 cell numbers would remain constant or possibly 
increase when exposed to the microenvironment found in premalignant tissue. 
4.2 Materials and Methods 
Oral HNSCC carcinogenesis 
Carcinogen-induced oral premalignant lesions and HNSCC were established in 
mice by administration of 4NQO at 5 mg/ml in propylene glycol stock in the drinking 
water (diluted to 50 )lg/ml) of 2 month old (at start) female C57BL/6 mice for 8 weeks, 
resulting in the development of premalignant oral lesions, or for 16 weeks to establish 
HNSCC. To monitor the development of premalignant oral lesions and HNSCC, the oral 
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cavities of the mice were examined by endoscopy using a Stryker 1.9 mm x 30° 
endoscope and a Stryker 1088 HD camera. The mice were sedated with inhaled 
isoflurane (Piramal Healthcare) during this procedure. 
Tongue tissue processing 
Control, premalignant, and HNSCC tongues were harvested from C57BL/6 mice 
and minced using a scalpel. The tissue was then enzymatically digested at 37°C with 0.23 
V of Liberase (Roche) for 4 hrs. The dissociated tissue was then washed with PBS and 
allowed to recover overnight. 
Generation ofTh17 cells 
Polarized Th 1 7 cells were obtained from Dr. Chrystal Palous' lab. The cells were 
produced by stimulating murine CD4+ cells from the spleen with TRP peptide (1 )lg/mL) 
along with incubation in polarizing media containing human IL-l ~ (10 ng/ml), human 
IL-2l (100 ng/ml), human IL-6 (100 ng/ml), human TGF-~ (30 ng/ml), anti-IL-4 
(lOug/ml) and anti-IFN-y (10 Jlg/ml) for 5 days. The cells were cultured for 5 days with 
the addition of human IL-2 (20 IV/ml) on day two. 
Treatment of splenocytes with supernatant 
Splenocytes were plated 100,000 per well in 48 well dish in 500lli of 100/0 RPMI 
media along with 500JlI of of supernatant from either control, premalignant, or HNSCC 
tissue was then added. The supernatant was formed after the enzymatically digested 
tongue tissue was stimulated for 4 hours at 37°C with 50 ng/ml PMA and 1 Jlg/ml 
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ionomycin without the addition of Brefeldin A. The cells incubated with the supernatant 
for 36 hours and supernatant was collected. 
Treatment of Th17 cells with supernatant 
Th17 cells were plated 100,000 per well in a 96 well plate in 50J-ll of their 
polarization media as previously described. Then 150J-ll of supernatant from either 
control, premalignant, or HNSCC tissue was then added. The supernatant was formed 
after the enzymatically digested tongue tissue was stimulated for 4 hours at 37°C with 50 
ng/ml PMA and 1 J-lg/ml ionomycin without the addition of Brefeldin A. The cells 
incubated with the supernatant for 36 hours and supernatant was collected. 
Cytokine bead array 
All reagents used for this assay were from BD unless otherwise specified. After 
36 hours the supernatant from the incubation of the Th17 cells with the tissue 
supernatants and splenocytes with supernatant were collect and analyzed. The levels of 
IL-17 were determined using a cytometric bead array Th 1 /Th2/Th 17 cytokine kit. The 
supernatants alone were also run to normalize the results. The average of the supernatants 
alone contained only 2.2 pg/ml. Relative amounts of each cytokine were analyzed using 
FCAP Array software. 
Effect of the Microenvironment on the C04+ population 33 
Statistical analysis 
Data are presented as mean ± standard deviation of the value. To compare one 
variable condition between groups, the two-tailed Student's t-test was used. Significance 
was reported in the 95% confidence interval. 
4.3 Results 
IL-17 A secretion from splenocytes decreases in the control microenvironment but with a 
subsequent increase in premalignant followed by an increasing trend again for HNSCC. 
In this study, we examined how the tumor microenvironment affected immune 
cells (splenocytes) and their secretion of IL-17. IL-17 secretion from cells exposed to 
control, premalignant or HNSCC microenvironments were compared to the levels of 
IL-17 secreted from cells incubated with 10% RPMI media alone. When compared to the 
media alone cells, IL-17 secretion decreased significantly when Th 17 cells were 
co-incubated with supernatant from control tongue, increased significantly when they 
were co-incubated with the supernatant from premalignant tongue, and saw a rising trend 
once again when co-incubated with supernatant from HNSCC tongue (Fig 4.1). Based on 
the data from the tongue lysate we were expecting to see an increase in IL-17 when 
treated with the premalignant supernatant and a decrease when treated with HNSCC 
supernatant. Contradictory to what we predicted, the levels of IL-17 did not decrease 
when the splenocytes were incubated with supernatant from HNSCC tissue. This could 
allude to the fact that the response at the tumor or lesion site is different than the systemic 
response. Once again, for example, Th17 cells and/or IL-17, along with other factors, 
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have been reported to induce inflammation and promote the initiation and early growth of 
tumors in three different murine models of cancer: immune-deficient mice, mice with 
chemical carcinogen-induced tumors, and mice with pathogen-induced tumors [79]. This 
occurs despite high levels ofIL-6, TGF-~, and IL-1, factors that promote mouse Th17 
cell development [98-100], suggesting that Th17 cell development may be suppressed in 












Media Control PM HNSCC 
Figure 4.1 Graphical representation of the results of cytometric bead array analysis of 
100,00 splenocytes cells co-incubated with control, 4NQO-treated premalignant, and 
4NQO-treated HNSCC tongue supernatants for 36 hours. Data are presented as the mean 
± standard deviation. *,p < 0.05; **,p < 0.01; *** p < 0.001 (Two-tailed Student's t-
test). 
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IL-17 A secretion from Th17 cells decreases in the control or HNSCC microenvironment 
but remains constant in the premalignant microenvironment. 
Because the response from the splenocytes was not what we expected, we decided 
to focus on the specific effect the microenvironment would have on the Th 1 7 cell 
population. Few studies have focused on the function of primary Th17 cells in the tumor 
microenvironment, the precise role(s) they may play in cancer progression remained 
unknown. In patients with epithelial cancer, Th 17 levels are an indicator of improved 
patient survival and reduced tumor progression. In mice with established tumors, studies 
have documented the potent antitumor efficacy of both Tc17 and Th17 populations. It is 
possible that Th 17 function may vary dependent on the cause, type and location of the 
cancer [97]. For example, Th17 cells and/or IL-17, along with other factors, have been 
reported to induce inflammation and promote the initiation and early growth of tumors in 
three different murine models of cancer: immune-deficient mice, mice with chemical 
carcinogen-induced tumors, and mice with pathogen-induced tumors [79]. This occurs 
despite high levels of IL-6, TGF-~, and IL-l., factors that promote mouse Th17 cell 
development [98-100]., suggesting that Th 17 cell development may be suppressed in the 
tumor microenvironment. In support of this, Th 17 cells are known to be tightly regulated 
by the local cytokine environment [78], and Treg cells have been shown to inhibit Th 17 
cell expansion [82,95]. 
In this study, we examined how the tumor microenvironment affected the 
secretion of IL-l 7. IL-17 secretion from cells exposed to control, premalignant or 
HNSCC microenvironments were compared to the levels of IL-17 secreted from cells 
incubated with media alone. When compared to the media alone cells, IL-17 secretion 
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decreased significantly when Th17 cells were co-incubated with supernatant from control 
tongue, increased significantly when they were co-incubated with the supernatant from 
premalignant tongue, and decreased significantly once again when co-incubated with 
supernatant from HNSCC tongue (Fig 4.1). This data suggests that the premalignant 
microenvironment facilitates the maintenance and function of Th 17 cells compared to the 

























Figure 4.2 Graphical representation of the results of cytometric bead array analysis of 
100,00 Th17 cells co-incubated with control, 4NQO-treated premalignant, and 4NQO-
treated HNSCC tongue supernatant for 36 hours. Data are presented as the mean ± 
standard deviation. *,p < 0.05; **,p < 0.01; *** p < 0.001 (Two-tailed Student's t-test). 
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4.4 Discussion 
Since their discovery only five years ago, Th17 cells have risen to prominence in 
studies of virology, autoimmune disease, inflammation, and immune responses to various 
parasites and fungi. While their role in the pathogenesis of many of these conditions is 
well defined, their function in the context of tumor immunology remains controversial. In 
ovarian cancer, the prevalence ofTh17 cells in tumor draining lymph nodes (TDLN) and 
blood is comparable to that of healthy donors. Although they make up only a small 
population of cells within the tumor microenvironment, they comprise a higher 
proportion than other immune cell subsets. In ovarian cancer patients, Th 17 cells are the 
sole source of IL-l 7 in the ascites, and the level of IL-l 7 in this fluid correlated 
positively with patient survival. Even after debulking, tumor-associated IL-17 was a 
negative predictor of death. The average survival rate of patients with ascites levels of 
greater than 220 pg/ml of IL-17 was 78 months, while that of patients with less than 220 
pg/ml was 27 months. In some types of epithelial cancer, Th17 cells constitute only a 
small fraction of the effector T cell population in the tumor microenvironment 
[78,82,95-96]. This has not been fully investigated in HNSCC because few studies have 
focused on Th 1 7 cells in the tumor microenvironment; therefore, it is difficult to predict 
the exact role(s) they may play in cancer progression. 
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When we treated Th17 cells with the supernatant from control, premalignant or HNSCC 
tissues, a significant increase in IL-l 7 A was observed only when the cells were 
co-cultured with supernatant from premalignant tissue. In contrast, a significant decrease 
was observed when the cells were co-cultured with supernatant from HNSCC tissue. This 
data further supports our findings of increased levels of IL-17 A in the microenvironment 
of premalignant tissue, as well as our,previous findings showing an increase in IL-17 A 
and Th 17 cells in the cervical1ymph nodes of mice bearing premalignant lesions. 
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Chapter 5 
General Discussion 
CHAPTER 5: GENERAL DISCUSSION 
Head and neck squamous cell carcinomas (HNSCCs) are associated with 
abnormal cell-mediated immunity at the primary tumor site [9], the levels of which vary 
widely from patient to patient. Immunosuppression in HNSCC has been postulated to 
occur in a hierarchical manner, in which the primary tumor region is the most affected 
site, followed by the draining lymph nodes [10]. This hierarchical phenomenon suggests 
that immunosuppression in HNSCC patients is mediated by a regional network of factors. 
It is likely that suppression at the site of the tumor and the affected lymph nodes plays a 
role in limiting the efficacy of current immunotherapy protocols. It also likely that the 
immune system exerts a selective pressure that gives rise to tumor variants that are able 
to manipulate the immune system. [11-16]. A greater understanding of the mechanisms 
the mediate local inhibition of immune function will aid in improving the effectiveness of 
adoptive immunotherapy for the treatment of cancers [10]. While we did see evidence of 
immune suppression in the microenvironment in fully established HNSCC, elevated 
levels of inflammatory cytokines were observed primarily during the premalignant stage. 
These premalignant tissues had significantly higher levels of IL-l 7, which is indicative of 
a heightened TH 1 7 cell response. Significantly higher levels of both IL-6 and IL-2 were 
also observed during this stage. IL-6 is required for Th 17 differentiation, and the levels of 
both IL-6 and IL-17 were decreased during HNSCC. IL-2 also plays an important role in 
the immune response as it is needed for the maintenance and expansion of effector T 
cells. There was also an increase in TGF-~ observed during the late premalignant stage, 
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which remained elevated through the late stage ofHNSCC. This increase in TGF-~, 
along with a decrease in IL-6, creates an ideal environment for Tregs. If there is an 
increase in the Treg population during the late premalignant stage, this may be indicative 
of the onset of immune suppression. If the timing and cause of this suppression can be 
identified, treatments able to halt or attenuate this process can be developed, allowing the 
effectiveness of current immunotherapeutic intervention to be enhanced. 
Since their discovery only five years ago, Th17 cells have risen to prominence in 
studies of virology, autoimmune disease, inflammation, and immune responses to various 
parasites and fungi. While their role in the pathogenesis of many of these conditions is 
well defined, their function in the context of tumor immunology remains controversial. In 
ovarian cancer, the prevalence of Th 17 cells in tumor draining lymph nodes and blood is 
comparable to that of healthy donors. Although they make up only a small population of 
cells within the tumor microenvironment, they are present in proportionally higher 
numbers compared to other immune cell subsets. In ovarian cancer patients, Th I 7 cells 
were found to be the sole source of IL-17 in the ascites, the levels of which correlated 
positively with patient survival. Even after debulking, tumor-associated IL-17 was a 
negative predictor of death hazard. The average survival rate of patients with levels of 
IL-17 greater than 220 pg/ml in ascites was 78 months, while that of patients with less 
than 220 pg/ml was 27 months. In some types of epithelial cancer, Th17 cells constitute 
only a small fraction of the effector T cell population in the tumor microenvironment 
[78,82,95-96] . 
Because few studies have focused on primary Th 1 7 cells in the tumor 
microenvironment in HNSCC, it is difficult to predict the exact role(s) they may play in 
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cancer progression. When splenocytes were incubated with control, premalignant, and 
HNSCC supernatant we saw a decrease in IL-l 7 levels with the control and an increase 
with both premalignant and HNSCC supernatant. When Th17 cells were cultured with 
the supernatant from control, premalignant, and HNSCC tissues, only exposure to the 
premalignant microenvironment induced a significant increase in IL-17. In contrast, a 
significant decrease was observed when Th 1 7 cells were co-cultured with supernatant 
from HNSCC tissue. This data further supports our finding of increased levels of IL-17 in 
the microenvironment of premalignant tissue, as well as previous findings by our 
laboratory showing an increase in IL-l 7 and Th 1 7 cells in the cervical lymph nodes of 
mice bearing premalignant lesions. If the timing and cause of this suppression can be 
identified, treatments able to halt or attenuate this process can be developed, allowing the 
effectiveness of current immunotherapeutic intervention to be enhanced. 
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